BR9808584A - Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos - Google Patents

Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos

Info

Publication number
BR9808584A
BR9808584A BR9808584-0A BR9808584A BR9808584A BR 9808584 A BR9808584 A BR 9808584A BR 9808584 A BR9808584 A BR 9808584A BR 9808584 A BR9808584 A BR 9808584A
Authority
BR
Brazil
Prior art keywords
homologous recombination
via homologous
vectors
same
mammalian cells
Prior art date
Application number
BR9808584-0A
Other languages
English (en)
Inventor
Mitchell E Reff
Richard Spence Barnett
Karen Retta Mclachlan
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26697516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9808584(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/819,866 external-priority patent/US5830698A/en
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of BR9808584A publication Critical patent/BR9808584A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Patente de Invenção: <B>"PROCESSO PARA INTEGRAR GENES EM SìTIOS ESPECìFICOS EM CéLULAS DE MAMìFEROS VIA RECOMBINAçãO HOMóLOGA E VETORES PARA OBTER OS MESMOS"<D>. Descreve-se um processo para obter interação específica de um DNA desejada em um sítio de marcação em uma célula de mamífero via recombinação homóloga. Este processo provê seleção reprodutível de linhagens de células em que um DNA desejado é integrado em um sítio ativo transcripcionalmente predeterminado anteriormente marcado com um plasmídeo marcador. O processo é particularmente apropriado para a produção de linhagens de células de mamífero que secretam proteínas de mamífero em níveis altos, em particular imunoglobulina. Vetores e combinações de vetor para uso no processo de clonagem objeto são também providos.
BR9808584-0A 1997-03-14 1998-03-09 Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos BR9808584A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/819,866 US5830698A (en) 1997-03-14 1997-03-14 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US09/023,715 US5998144A (en) 1997-03-14 1998-02-13 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
PCT/US1998/003935 WO1998041645A1 (en) 1997-03-14 1998-03-09 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same

Publications (1)

Publication Number Publication Date
BR9808584A true BR9808584A (pt) 2000-05-23

Family

ID=26697516

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808584-0A BR9808584A (pt) 1997-03-14 1998-03-09 Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos

Country Status (21)

Country Link
US (3) US6413777B1 (pt)
EP (1) EP0981637B1 (pt)
JP (1) JP4128227B2 (pt)
CN (1) CN1175111C (pt)
AT (1) ATE296356T1 (pt)
AU (1) AU737155B2 (pt)
BR (1) BR9808584A (pt)
CA (1) CA2283740C (pt)
CZ (1) CZ293355B6 (pt)
DE (1) DE69830312T2 (pt)
ES (1) ES2242997T3 (pt)
ID (1) ID24565A (pt)
IL (1) IL131746A0 (pt)
IN (1) IN189732B (pt)
NO (1) NO994397L (pt)
PL (1) PL191251B1 (pt)
PT (1) PT981637E (pt)
RO (1) RO120148B1 (pt)
RU (1) RU2004107694A (pt)
TW (1) TWI232239B (pt)
WO (1) WO1998041645A1 (pt)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
IL131746A0 (en) * 1997-03-14 2001-03-19 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
KR20010032861A (ko) 1997-12-08 2001-04-25 캘리포니아 인스티튜트 오브 테크놀로지 폴리뉴클레오티드 및 폴리펩티드 서열을 형성하는 방법
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
EP1228237A1 (en) * 1999-11-01 2002-08-07 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
DK1297170T3 (en) * 2000-06-23 2016-03-14 Novozymes As A process for stable chromosomal integration of multiple copies of the genes
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
EA007905B1 (ru) 2001-11-16 2007-02-27 Байоджен Айдек Инк. Полицистронная экспрессия антител
US7164056B2 (en) * 2002-05-03 2007-01-16 Pioneer Hi-Bred International, Inc. Gene targeting using replicating DNA molecules
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20040170614A1 (en) * 2002-10-30 2004-09-02 Gail Bishop Somatic cell gene targeting vectors and methods of use thereof
PT1583830E (pt) * 2003-01-07 2006-11-30 Symphogen As Método para produzir proteínas policlonais recombinantes
DE10303937A1 (de) * 2003-01-31 2004-08-12 Icon Genetics Ag Pflanzentransformation mit Assemblierung einer gewünschten Sequenz in Vivo
ES2322809T3 (es) * 2003-01-31 2009-06-29 Icon Genetics Gmbh Metodo de transformacion de plantas con ensamblaje in vivo de un tratamiento.
NZ607886A (en) * 2003-03-19 2014-09-26 Biogen Idec Inc Nogo receptor binding protein
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CA2897608C (en) * 2003-05-09 2018-07-31 Duke University Cd20-specific antibodies and methods employing same
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005000898A2 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
WO2005024015A1 (en) * 2003-09-04 2005-03-17 Medarex, Inc. Expression vector
US8030833B2 (en) * 2003-09-19 2011-10-04 The Board Of Trustees Of The University Of Illinois Electron emission device incorporating free standing monocrystalline nanowires
US7344753B2 (en) * 2003-09-19 2008-03-18 The Board Of Trustees Of The University Of Illinois Nanostructures including a metal
US7935862B2 (en) * 2003-12-02 2011-05-03 Syngenta Participations Ag Targeted integration and stacking of DNA through homologous recombination
CA2554054C (en) 2004-01-20 2013-06-04 Merus B.V. Mixtures of binding proteins
BRPI0512500A (pt) 2004-06-24 2008-03-11 Biogen Idec Inc tratamento ou condições envolvendo desmielinação
WO2006007853A2 (en) 2004-07-20 2006-01-26 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
JP5060293B2 (ja) 2004-08-03 2012-10-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド 神経機能におけるｔａｊ
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
EP1838736B1 (en) 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto binding molecules
CN100381573C (zh) * 2005-04-14 2008-04-16 北京天广实生物技术有限公司 快速构建目标基因高表达的哺乳动物细胞株的体系和方法
PT1904104E (pt) 2005-07-08 2013-11-21 Biogen Idec Inc Anticorpos sp35 e suas utilizações
CA2617930A1 (en) * 2005-08-09 2007-03-29 Revivicor, Inc. Transgenic ungulates expressing ctla4-ig and uses thereof
KR20080080109A (ko) 2005-11-04 2008-09-02 바이오겐 아이덱 엠에이 인코포레이티드 도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
EP1965827B1 (en) 2005-12-02 2015-02-25 Biogen Idec MA Inc. Treatment of conditions involving demyelination
WO2007089601A2 (en) 2006-01-27 2007-08-09 Biogen Idec Ma Inc. Nogo receptor antagonists
PT2099826E (pt) 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
LT2740744T (lt) 2007-01-09 2018-05-10 Biogen Ma Inc. Sp35 antikūnai ir jų panaudojimas
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2008097503A2 (en) 2007-02-02 2008-08-14 Biogen Idec Ma Inc. Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
JP5674469B2 (ja) * 2007-10-11 2015-02-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
AU2008335178A1 (en) * 2007-12-10 2009-06-18 Ablexis Llc Methods for sequential replacement of targeted region by homologous recombination
CA2729961C (en) * 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
EP3889265A1 (en) 2008-09-30 2021-10-06 Ablexis, LLC Transgenic mice for the production of chimeric antibodies
MX2011006422A (es) 2008-12-19 2011-09-15 Panima Pharmaceuticals Ag Autoanticuerpos humanos anti-alfa-sinucleina.
CA2748757A1 (en) 2008-12-31 2010-07-08 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
AU2010228990A1 (en) 2009-03-24 2011-10-27 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against LIGHT and uses thereof
EP2484761A4 (en) 2009-10-01 2013-11-27 Toto Ltd DNA CONSTRUCT AND METHOD FOR PRODUCING RECOMBINANT CHO CELLS THEREWITH
KR102117771B1 (ko) 2010-03-31 2020-06-02 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
WO2011136739A1 (en) * 2010-04-30 2011-11-03 Temasek Life Sciences Laboratory Limited Fragment switch: a reverse genetic approach
PL2591006T3 (pl) 2010-07-09 2019-10-31 Bioverativ Therapeutics Inc Przetwarzalne cząsteczki jednołańcuchowe i polipeptydy wytworzone przy ich zastosowaniu
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
JP6092782B2 (ja) 2010-11-16 2017-03-08 エクセリミューン， インコーポレイテッド 組換えタンパク質の製造方法
JP5209693B2 (ja) * 2010-12-10 2013-06-12 ロンザ・バイオロジクス・ピーエルシー Ｃｈｏ細胞において組換えタンパク質を発現する方法
EP2651979B1 (en) 2010-12-17 2019-08-28 Neurimmune Holding AG Human anti-sod1 antibodies
EA030777B9 (ru) 2011-06-23 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Анти-альфа-синуклеинсвязывающие молекулы
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
US10233424B2 (en) 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
US9175072B2 (en) 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US8962315B2 (en) 2011-12-22 2015-02-24 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
KR102382304B1 (ko) 2012-04-20 2022-04-04 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
US9834786B2 (en) 2012-04-25 2017-12-05 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
BR112014027813A2 (pt) 2012-05-07 2017-08-08 Dow Agrosciences Llc métodos e composições para integração de transgenes direcionada mediada por nuclease
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
AU2013329421A1 (en) 2012-10-09 2015-04-30 Biogen Ma Inc. Combination therapies and uses for treatment of demyelinating disorders
KR102234324B1 (ko) 2012-12-21 2021-03-31 바이오젠 엠에이 인코포레이티드 인간 항-타우 항체
EP3517545A1 (en) 2012-12-31 2019-07-31 Neurimmune Holding AG Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
PT3889173T (pt) 2013-02-15 2023-10-10 Bioverativ Therapeutics Inc Gene do fator viii otimizado
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
MX2017004213A (es) 2014-09-30 2017-07-19 Neurimmune Holding Ag Anticuerpo anti-repeticiones de dipeptido (dpr) derivados de humano.
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
CN106191040B (zh) * 2015-04-30 2021-09-14 杭州菁因康生物科技有限公司 基因打靶方法
CN108472337B (zh) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 因子ix融合蛋白以及其制备和使用方法
RS63548B1 (sr) 2016-02-01 2022-09-30 Bioverativ Therapeutics Inc Optimizovani geni faktora viii
WO2017214376A1 (en) 2016-06-10 2017-12-14 Elwha Llc Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function
KR20190039134A (ko) 2016-07-13 2019-04-10 바이오젠 엠에이 인코포레이티드 Lingo-1 길항제의 투약 섭생 및 탈수초성 질환의 치료를 위한 용도
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
AU2017368328A1 (en) 2016-12-02 2019-07-18 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
JP2020505424A (ja) 2017-01-31 2020-02-20 バイオベラティブ セラピューティクス インコーポレイテッド 因子ｉｘ融合タンパク質ならびにその製造および使用方法
TW202003551A (zh) 2018-03-28 2020-01-16 美商必治妥美雅史谷比公司 介白素-2/介白素-2受體阿法融合蛋白及其使用方法
US20210238289A1 (en) 2018-06-04 2021-08-05 Biogen Ma Inc. Anti-vla-4 antibodies having reduced effector function
CN110607326B (zh) * 2018-06-15 2022-11-29 江苏省农业科学院 非强启动式的外源基因表达法及其在具有毒性的目标蛋白表达中的应用
WO2020072480A1 (en) * 2018-10-01 2020-04-09 Lonza Ltd Ssi cells with predictable and stable transgene expression and methods of formation
JP2022520088A (ja) 2019-02-13 2022-03-28 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 抗末梢リンパ節アドレッシン抗体およびその使用
IL310963A (en) 2021-08-23 2024-04-01 Bioverativ Therapeutics Inc Production of closed DNA with inverted repeat sequences
KR20240049332A (ko) 2021-08-23 2024-04-16 바이오버라티브 테라퓨틱스 인크. 최적화된 인자 viii 유전자
CN118019758A (zh) 2021-09-30 2024-05-10 比奥维拉迪维治疗股份有限公司 编码免疫原性降低的因子viii多肽的核酸

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
DK0452484T3 (da) 1989-11-06 1996-10-14 Cell Genesys Inc Fremstilling af proteiner ved homolog rekombination
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
WO1993024642A1 (en) * 1992-06-04 1993-12-09 Exemplar Corporation Insertion of heterologous dna outside of known chromosomal genes
MX9305183A (es) * 1992-08-27 1994-05-31 Us Agriculture Intron portatil, molecula de adn genomico viral, virus vivo y vacuna que los contiene y metodo para su obtencion.
US5648267A (en) * 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
IL131746A0 (en) 1997-03-14 2001-03-19 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same

Also Published As

Publication number Publication date
US6413777B1 (en) 2002-07-02
PL335695A1 (en) 2000-05-08
PT981637E (pt) 2005-09-30
US20040166528A1 (en) 2004-08-26
US6841383B2 (en) 2005-01-11
CA2283740C (en) 2006-06-27
CZ316299A3 (cs) 2000-02-16
PL191251B1 (pl) 2006-04-28
RU2004107694A (ru) 2005-08-27
IN189732B (pt) 2003-04-19
EP0981637B1 (en) 2005-05-25
DE69830312T2 (de) 2006-02-02
NO994397D0 (no) 1999-09-10
JP4128227B2 (ja) 2008-07-30
CZ293355B6 (cs) 2004-04-14
IL131746A0 (en) 2001-03-19
ID24565A (id) 2000-07-27
ATE296356T1 (de) 2005-06-15
CA2283740A1 (en) 1998-09-24
US20020192820A1 (en) 2002-12-19
AU6443598A (en) 1998-10-12
EP0981637A1 (en) 2000-03-01
CN1175111C (zh) 2004-11-10
US7235360B2 (en) 2007-06-26
ES2242997T3 (es) 2005-11-16
AU737155B2 (en) 2001-08-09
TWI232239B (en) 2005-05-11
DE69830312D1 (de) 2005-06-30
RO120148B1 (ro) 2005-09-30
NO994397L (no) 1999-11-09
WO1998041645A1 (en) 1998-09-24
JP2001516221A (ja) 2001-09-25
CN1255166A (zh) 2000-05-31

Similar Documents

Publication Publication Date Title
BR9808584A (pt) Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
MY137837A (en) Novel method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
DK1097211T3 (da) Ekspression af eukaryote peptider i planteplastider
MX9605542A (es) Produccion de proteinas y liberacion de proteinas.
BR8200191A (pt) Celula viva renina preprorrenina prorrenina processo para obter expressao de preporrenina prorrenina e renina gene de prorrenina preprorrenina e renina e coli material dna recombinador saccharomyces cerevisiae polipetidio processo para exprimir um gene
ATE404684T1 (de) Methoden und zusammensetzungen zur transformation von zellen
HUP9700428A2 (hu) Célsejtspecifikus vektorok gének beépítésére, a vektorokat tartalmazó gyógyászati készítmények és azok alkalmazása
DK1042461T3 (da) Ekspressionskloning i filiforme svampe
ATE303448T1 (de) Duale selektionkassette und sie enthaltende plasmide
NO964445D0 (no) DNA-sekvens, vektor, vertscelle og fremgangsmåte for transfeksjon av hematopoeseceller med eksogen DNA
BR0009393A (pt) Polipeptìdeo, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, método para a produção do polipeptìdeo, uso de um polipeptìdeo, e, composição detergente
WO2002006457A3 (en) Novel lipase genes
ATE526818T1 (de) Gentechnisch hergestellte wasserlinse
ATE244311T1 (de) Expressionssystem von antikörpern bei homologischer rekombinierung in murinezellen
DK1025245T3 (da) Hurtig etablering af stabile pattedyrscelelinjer, der producerer höje koncentrationer af rekombinante proteiner
AU5659898A (en) Gene-trapping construct for the identification and isolation of genes
DE59812625D1 (de) Retrovirale pseudotyp-vektoren mit modifizierten oberflächen-hüllproteinen und verfahren zu ihrer herstellung für den selektiven gentransfer
BR9610738A (pt) Integração aperfeiçoada de dna exógeno transferido para as células eucarióticas
NO892029L (no) Fremgangsmaate ved spesifikk genetisk manipulering av mikroorganisme.
TR200000858T2 (tr) Meyve oluşumu ve gelişimini güçlendirme yöntemleri
Kidd et al. Peptide maps comparing subunits of maize chloroplast and type II nuclear DNA-dependent RNA polymerases.
ATE72837T1 (de) Vielfach amplifizierbare vektoren fuer hohe expression exogener dns.
ATE49998T1 (de) Klonierungsvektoren, die eine restriktionsstellenbank enthalten und deren herstellung.
GB2321702B (en) Methods and means relating to retrotransposon and retroviral integration
ATE348179T1 (de) Gebrauch von beta-rekombinase in eukaryotischen zellen, speziell für transgene arbeiten

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements